Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/4/2025

Duration for Stopping ACE Inhibitors or ARBs Before Aldosterone and Renin Testing

Rationale for Medication Withdrawal

  • ACE inhibitors and ARBs should be discontinued for at least 2 weeks prior to testing for aldosterone and renin activity to avoid false negative results, as they significantly affect the renin-angiotensin-aldosterone system (RAAS), causing increased renin levels and decreased aldosterone levels, according to the American College of Cardiology 1
  • The American College of Cardiology and American Heart Association acknowledge that medications affecting the RAAS must be withdrawn before testing, as stated in the 2017 ACC/AHA guidelines, although they do not specify an exact timeframe 2, 3

Special Considerations

  • Patients should maintain unrestricted salt intake and have serum potassium in the normal range during the testing period, as recommended by the American College of Cardiology and American Heart Association 2, 3, 1
  • Diuretics, including spironolactone and eplerenone, should be withdrawn for at least 4 weeks before testing, as they can significantly alter the aldosterone-to-renin ratio (ARR), according to the American College of Cardiology 1

Medication Management for Accurate Aldosterone and Renin Testing

Medication Withdrawal and Testing Considerations

  • The American Heart Association recommends that patients maintain unrestricted salt intake during the testing period, and serum potassium should be in the normal range during testing, as hypokalemia can suppress aldosterone production 4
  • The American Heart Association suggests monitoring for rebound hypokalemia, especially in patients with primary aldosteronism, when MRAs are withdrawn 5
  • Potassium supplementation should be discontinued or reduced when initiating aldosterone testing, and triple combination therapy with ACE inhibitors, ARBs, and MRAs should generally be avoided due to hyperkalemia risk 5

Medication Interference and Testing Pitfalls

  • Centrally acting antihypertensives, such as alpha-methyldopa, can interfere with the accurate measurement of plasma renin activity and aldosterone levels 4